WEST CHESTER, PA — Pathways Neuro Pharma, Inc., a Chester County-based biotechnology firm, has secured a U.S. patent for its groundbreaking neuroreceptor technology.
The patent, dubbed “Neuroreceptor Compositions and Methods of Use,” carries the U.S. Patent Number US 11,760,788, issued on September 19, 2023. This technological breakthrough spotlights Pathways’ commitment to developing innovative neuroreceptor compositions with extensive applications.
The patented technology represents a considerable stride forward in Pathways’ development pipeline in behavioral health. It holds the promise of transforming the treatment landscape for disorders like alcoholism, substance abuse, depression, and related neurological conditions.
“The patent reflects our team’s dedication to pushing the boundaries of neuroscientific research,” said Anthony Mack, CEO of Pathways Neuro Pharma, Inc. “We take pride in our contribution to the progression of neuropharmacology and remain steadfast in our quest to translate these discoveries into tangible improvements in patient care.”
As it stands, this patent places Pathways at the forefront of the neuropharmacology arena. The company is keen on continuing its research and development initiatives, with sights set on commercializing this technology in the near future. With the potential to revolutionize neurological treatment, industry watchers are keeping a close eye on Pathways’ next move.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.